arrow
T

Tuğba Yavuzşen

Dokuz Eylül University
H指数:22
被引数:2,106

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Transcript-Level Expression Patterns of Necroptosis-Related Genes RIPK1, RIPK3, and MLKL in Surgically Resected Non-Small Cell Lung Cancer: An Exploratory Single-Center Study

坏死性凋亡相关基因RIPK1、RIPK3和MLKL在手术切除的非小细胞肺癌中的转录水平表达模式:一项探索性单中心研究

2026-09-200
OA
Tyrosine Kinase Inhibitor Therapy in Metastatic Medullary Thyroid Carcinoma: Real-World Data from Turkish Oncology Group

转移性髓样甲状腺癌中的酪氨酸激酶抑制剂治疗:土耳其肿瘤学组的真实世界数据

2026-03-190
OA
Chronic kidney disease and denosumab in metastatic bone disease: A multicenter Turkish cohort study on severe hypocalcemia, skeletal events, and survival

慢性肾病与地诺单抗在骨转移性疾病中的应用:一项关于严重低钙血症、骨骼事件和生存情况的多中心土耳其队列研究

2025-11-210
OAAI
Efficacy of Anti-VEGF and Anti-EGFRs in Microsatellite Instable (MSI-H) Metastatic Colorectal Cancer in a Turkish Oncology Group (TOG) Cohort Study

抗VEGF和抗EGFRs在微卫星不稳定(MSI-H)转移性结直肠癌中的疗效:土耳其肿瘤学组(TOG)队列研究

2025-11-180
OAAI
Self-administered versus lymphedema therapist-administered complex decongestive therapy protocol in breast cancer-related lymphedema: a non-inferiority randomized controlled trial with three-month follow-up

自行管理与淋巴水肿治疗师管理的复杂消肿疗法方案在乳腺癌相关淋巴水肿中的应用:一项具有三个月随访的非劣效性随机对照试验

2025-05-060
OA
Efficacy of everolimus plus hormonal treatment after cyclin-dependent kinase inhibitor; real-life experience, A TOG study

细胞周期蛋白依赖性激酶抑制剂后依维莫司加激素治疗的疗效; 现实生活经验,TOG研究

2024-08-090
PRE
The effect of low HER2 expression on treatment outcomes in metastatic hormone receptor positive breast cancer patients treated with a combination of a CDK4/6 inhibitor and endocrine therapy: A multicentric retrospective study

低HER2表达对接受CDK4/6抑制剂联合内分泌治疗的转移性激素受体阳性乳腺癌患者治疗结局的影响: 一项多中心回顾性研究

BREAST
IF7.9
2023-08-019
OAAI
Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer

瑞博西尼或帕博西尼联合来曲唑治疗激素受体阳性/HER2-negative转移性乳腺癌的疗效

2023-05-0310
PRE
Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy (vol 23, 136, 2023)

在CDK 4/6抑制剂治疗下疾病进展的激素阳性晚期乳腺癌患者中后续治疗的疗效 (第23卷,136,2023)

2023-02-272
OAAI
Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

在CDK 4/6抑制剂治疗下疾病进展的激素阳性晚期乳腺癌患者的后续治疗效果

2023-02-1016
OAAI
Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter study
BREAST
IF7.9
2022-12-0112
OAAI